Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours Β· Estimated delivery Aug 28 - Sep 2
Treatment can be a little bit more challenging because it's not just a one injection, one pill, and that's those levels maintained
The CAS registry number for AOD9604 is 221231-10-3
Common compounded formulations include: Tirzepatide with cyanocobalamin (B12) : Pink to red Tirzepatide with glycine and B12 : Pink to red (glycine does not affect color) Tirzepatide with methylcobalamin : Pink to red (similar shade to cyanocobalamin) Tirzepatide with niacinamide : Clear to very faint yellow (no B12 means no pink) Visual comparison table Notice that one factor remains constant across every formulation in that table: clarity
Animal studies have shown that when beta-3 adrenergic receptors were genetically removed, chronic AOD-9604 treatment produced no changes in weight or lipolysis, confirming the importance of this pathway
Mutations in DDHD2, encoding an intracellular phospholipase A1, cause a recessive form of complex hereditary spastic paraplegia
US$ 28.50
US$ 24.36
US$ 20.41
US$ 26.53
